New oral anticoagulants for the treatment of acute venous thromboembolism: are they safer than vitamin K antagonists? A meta-analysis of the interventional trials

Internal and Emergency Medicine

Volumn 10, Issue 4, 2015, Pages 499-506

  Loffredo, Lorenzo ^a   Perri, Ludovica ^a   Del Ben, Maria ^a   Angelico, Francesco ^a   Violi, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Myocardial infarction; New oral anticoagulants; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; VITAMIN K GROUP;

ACUTE DISEASE; ANTAGONISTS AND INHIBITORS; DOUBLE BLIND PROCEDURE; HUMAN; META ANALYSIS; MYOCARDIAL INFARCTION; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); VENOUS THROMBOEMBOLISM;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANTICOAGULANTS; DOUBLE-BLIND METHOD; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84933180082     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-014-1171-7     Document Type: Article

References (35)

1. White RH (2003) The epidemiology of venous thromboembolism. Circulation 107:I4–I8
2. Goldhaber SZ, Bounameaux H (2012) Pulmonary embolism and deep vein thrombosis. Lancet 379:1835–1846
3. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F et al (2012) Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines, 9th edn. Chest 141:e195S–e226S
4. Guyatt GH, Eikelboom JW, Gould MK, Garcia DA, Crowther M et al (2012) Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines, 9th edn. Chest 141:e185S–e194S
5. Violi F, Perri L, Loffredo L (2013) Should all acutely ill medical patients be treated with antithrombotic drugs? A review of the interventional trials. Thromb Haemost 109:589–595
6. Violi F, Perri L, Loffredo L (2013) Interventional trials with anticoagulants in acutely ill medical patients: a methodological pitfall? Intern Emerg Med 8:461–464
7. Fareed J, Thethi I, Hoppensteadt D (2012) Old versus new oral anticoagulants: focus on pharmacology. Annu Rev Pharmacol Toxicol 52:79–99
8. Ferro D, Loffredo L, Polimeni L, Violi F (2007) Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy. Intern Emerg Med 2:24–28
9. Baker WL, Phung OJ (2012) Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. Circ Cardiovasc Qual Outcomes 5:711–719
10. Kwong JS, Lam YY, Yan BP, Yu CM (2013) Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials. Cardiovasc Drugs Ther 27:23–35
11. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM et al (2012) Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines, 9th edn. Chest 141:e44S–e88S
12. Skanes AC, Healey JS, Cairns JA, Dorian P, Gillis AM et al (2012) Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 28:125–136
13. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ (2012) Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 110:453–460
14. Wasserlauf G, Grandi SM, Filion KB, Eisenberg MJ (2013) Meta-analysis of rivaroxaban and bleeding risk. Am J Cardiol 112:454–460
15. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151
16. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N et al (2013) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955–962
17. Artang R, Rome E, Nielsen JD, Vidaillet HJ (2013) Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol 112:1973–1979
18. Uchino K, Hernandez AV (2012) Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 172:397–402
19. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12
20. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097
21. Higgins JGS (2011) Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration. http://handbook.cochrane.org/
22. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748
23. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
24. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808
25. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352
26. Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S et al (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406–1415
27. Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW et al (2005) Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 293:681–689
28. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510
29. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, et al. (2013) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation
30. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297
31. Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A (2012) Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 345:e7498
32. van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA et al (2014) Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 12:320–328
33. Gomez-Outes A, Terleira-Fernandez AI, Lecumberri R, Suarez-Gea ML, Vargas-Castrillon E (2014) Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res 134:774–782
34. Tomblyn MR, Rizzo JD (2007) Are there circumstances in which phase 2 study results should be practice-changing? Hematol Am Soc Hematol Educ Progr: 489–492
35. Manly DA, Boles J, Mackman N (2011) Role of tissue factor in venous thrombosis. Annu Rev Physiol 73:515–525